Product
Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
1 clinical trial
1 indication
Indication
Advanced Solid Tumor CancerClinical trial
A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic TumorsStatus: Recruiting, Estimated PCD: 2025-08-18